244 related articles for article (PubMed ID: 18469550)
1. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):288-93. PubMed ID: 18469550
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients.
Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
Thromb Res; 2008; 123(1):159-65. PubMed ID: 18433842
[TBL] [Abstract][Full Text] [Related]
3. Influences of argatroban on five fibrinogen assays.
Zhang L; Yang J; Zheng X; Fan Q; Zhang Z
Int J Lab Hematol; 2017 Dec; 39(6):641-644. PubMed ID: 28766891
[TBL] [Abstract][Full Text] [Related]
4. Coagulation laboratory testing in patients treated with argatroban.
Walenga JM; Fasanella AR; Iqbal O; Hoppensteadt DA; Ahmad S; Wallis DE; Bakhos M
Semin Thromb Hemost; 1999; 25 Suppl 1():61-6. PubMed ID: 10357154
[TBL] [Abstract][Full Text] [Related]
5. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
6. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin.
Li N; He S; Blombäck M; Hjemdahl P
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):407-13. PubMed ID: 17138937
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
Eller T; Busse J; Dittrich M; Flieder T; Alban S; Knabbe C; Birschmann I
Clin Chem Lab Med; 2014 Jun; 52(6):835-44. PubMed ID: 24406289
[TBL] [Abstract][Full Text] [Related]
8. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
9. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing.
Walenga JM; Drenth AF; Mayuga M; Hoppensteadt DA; Prechel M; Harder S; Watanabe H; Osakabe M; Breddin HK
Clin Appl Thromb Hemost; 2008 Jul; 14(3):325-31. PubMed ID: 18586683
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyethyl starch enhances argatroban-mediated decreases in clot propagation and strength by diminishing thrombin-fibrinogen interactions.
Nielsen VG; Kirklin JK
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):49-54. PubMed ID: 17179827
[TBL] [Abstract][Full Text] [Related]
11. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
12. Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.
Guy S; Kitchen S; Van Veen JJ
Br J Haematol; 2018 Feb; 180(4):594-597. PubMed ID: 27785784
[No Abstract] [Full Text] [Related]
13. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation during use of a left ventricular assist device.
Takahama T; Kanai F; Onishi K
ASAIO J; 2000; 46(3):354-7. PubMed ID: 10826751
[TBL] [Abstract][Full Text] [Related]
15. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
[TBL] [Abstract][Full Text] [Related]
16. The effects of argatroban on thrombin generation and hemostatic activation in vitro.
Tanaka KA; Szlam F; Katori N; Sato N; Vega JD; Levy JH
Anesth Analg; 2004 Nov; 99(5):1283-1289. PubMed ID: 15502018
[TBL] [Abstract][Full Text] [Related]
17. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
[TBL] [Abstract][Full Text] [Related]
18. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.
Gosselin RC; King JH; Janatpur KA; Dager WH; Larkin EC; Owings JT
Arch Pathol Lab Med; 2004 Oct; 128(10):1142-5. PubMed ID: 15387708
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
[TBL] [Abstract][Full Text] [Related]
20. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing.
Genzen JR; Miller JL
Am J Clin Pathol; 2005 Oct; 124(4):586-93. PubMed ID: 16146819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
